Rockefeller Capital Management
BBC icon

Rockefeller Capital Management’s Virtus Biotech Clinical Trials ETF BBC Stock Holding History

Rockefeller Capital Management’s Portfolio BBC Stock Details BBC Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q1 		– Sell
-28,912
Closed -$722K – 2142
2022
Q4 		$722K Sell
28,912
-7,502
-21% -$187K ﹤0.01% 1128
2022
Q3 		$894K Buy
+36,414
New +$928K ﹤0.01% 1054

Other funds holding BBC

Citadel Advisors
Citadel Advisors Miami, Florida $875B AUM 40.91% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $445B AUM 25.58% 1-Year Est. Return
Royal Bank of Canada
Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $1.28T AUM 58.89% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
US Bancorp
US Bancorp Minneapolis, Minnesota $91.6B AUM 29.2% 1-Year Est. Return
FDCDDQ
Federation des caisses Desjardins du Quebec Levis, Quebec, Canada $32.7B AUM 35.71% 1-Year Est. Return
DSC
Duncker Streett & Co St. Louis, Missouri $591M AUM 26.48% 1-Year Est. Return
HI
Harbour Investments Madison, Wisconsin $7.43B AUM 24.49% 1-Year Est. Return
Osaic Holdings
Osaic Holdings Scottsdale, Arizona $85.1B AUM 27.35% 1-Year Est. Return

Rockefeller Capital Management's BBC Position: Q1 2023 in Review

Rockefeller Capital Management sold out of Virtus Biotech Clinical Trials ETF (BBC) in Q1 2023, closing a stake of 28,912 shares — an estimated $722K sold.

Rockefeller Capital Management first reported a position in BBC in Q3 2022 and held it in 2 quarters. The position peaked at $894K in Q3 2022. 16 funds tracked by Wall St. Rank hold BBC as of Q1 2023.

  • Rockefeller Capital Management reported no remaining Virtus Biotech Clinical Trials ETF position as of Q1 2023 after selling out during the quarter.
  • Rockefeller Capital Management sold 28,912 Virtus Biotech Clinical Trials ETF shares in Q1 2023, an estimated $722K.
  • Rockefeller Capital Management first reported a position in Virtus Biotech Clinical Trials ETF in Q3 2022 and held it in 2 quarters.
  • Rockefeller Capital Management's Virtus Biotech Clinical Trials ETF position peaked at $894K in Q3 2022.
  • 16 funds tracked by Wall St. Rank held Virtus Biotech Clinical Trials ETF as of Q1 2023.

Based on Rockefeller Capital Management's 13F filing for Q1 2023, filed 16 May 2023.